Category: 158407-04-6

Application of 158407-04-6, The reaction rate of a catalyzed reaction is faster than the reaction rate of the uncatalyzed reaction at the same temperature.158407-04-6, Name is tert-Butyl 4-(bromomethyl)piperidine-1-carboxylate, molecular formula is C11H20BrNO2. In a Patent£¬once mentioned of 158407-04-6

PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF

Provided herein are compounds, compositions, and methods useful for inhibiting protein tyrosine phosphatase, e.g., protein tyrosine phosphatase non-receptor type 2 (PTPN2) and/or protein tyrosine phosphatase non-receptor type 1 (PTPN1), and for treating related diseases, disorders and conditions favorably responsive to PTPN1 or PTPN2 inhibitor treatment, e.g., a cancer or a metabolic disease.

A reaction mechanism is the microscopic path by which reactants are transformed into products. Each step is an elementary reaction. In my other articles, you can also check out more blogs about 158407-04-6

Reference£º
Piperidine – Wikipedia,
Piperidine | C5H22522N – PubChem

 

Chemistry is traditionally divided into organic and inorganic chemistry. SDS of cas: 158407-04-6. The former is the study of compounds containing at least one carbon-hydrogen bonds.In a patent£¬Which mentioned a new discovery about 158407-04-6

PIPERIDINE-CONTAINING COMPOUNDS AND USE THEREOF

A method for preventing and/or treating a metabolic disease, cerebrovascular disease, etc. which comprises administering to a mammal an effective amount of the compound of the formula (I) wherein all symbols have the same meanings as defined in the specification; a salt thereof, an N-oxide thereof, a solvate thereof, or a prodrug thereof. And a novel compound of the formula (I-1): wherein all symbols have the same meanings as defined in the specification; a salt thereof, an N-oxide thereof, a solvate thereof, or a prodrug thereof has an anti-diabetic effect and a neuroprotective effect. Accordingly, the compound of the formula (I) and the compound of the formula (I-1) are useful in a method for preventing and/or treating for a metabolic disease such as diabetes, cerebrovascular disease such as stroke, etc.

Note that a catalyst decreases the activation energy for both the forward and the reverse reactions and hence accelerates both the forward and the reverse reactions.SDS of cas: 158407-04-6, you can also check out more blogs about158407-04-6

Reference£º
Piperidine – Wikipedia,
Piperidine | C5H22573N – PubChem

 

Chemistry is the experimental and theoretical study of materials on their properties at both the macroscopic and microscopic levels.In a patent£¬ HPLC of Formula: C11H20BrNO2, Which mentioned a new discovery about 158407-04-6

THIENOPYRIDAZINE COMPOUNDS, THEIR PREPARATIONS, PHARMACEUTICAL COMPOSITIONS AND USES

The present invention relates to thienopyridazine compounds of formula (I), their pharmaceutically acceptable salts or hydrates, wherein R1 and R2 are independently H or C1-4 alkyl, R3 is a saturated or unsaturated 5- or 6- membered ring containing N, S or O, or its optical isomers, R4 is a halophenyl monosubstituted or disubstituted at any position. The present invention provides the preparation methods of these compounds, pharmaceutical compositions containing these compounds and the uses of these compounds, particularly in treating cancer.

I hope this article can help some friends in scientific research. I am very proud of our efforts over the past few months and hope to 158407-04-6, help many people in the next few years.HPLC of Formula: C11H20BrNO2

Reference£º
Piperidine – Wikipedia,
Piperidine | C5H22467N – PubChem

 

A catalyst don’t appear in the overall stoichiometry of the reaction it catalyzes, Formula: C11H20BrNO2, but it must appear in at least one of the elementary reactions in the mechanism for the catalyzed reaction. 158407-04-6, Name is tert-Butyl 4-(bromomethyl)piperidine-1-carboxylate, molecular formula is C11H20BrNO2. In a Patent, authors is £¬once mentioned of 158407-04-6

AZAINDOLES AND METHODS OF USE THEREOF

Disclosed are compounds according to Formula (I) or (II), and pharmaceutical compositions comprising them. Also disclosed are therapeutic methods, e.g., of treating kidney diseases, using the compounds of Formula (I) or (II). (Formulae (I, (II))

I hope this article can help some friends in scientific research. I am very proud of our efforts over the past few months and hope to 158407-04-6, help many people in the next few years.Formula: C11H20BrNO2

Reference£º
Piperidine – Wikipedia,
Piperidine | C5H22546N – PubChem

 

158407-04-6, Catalysts function by providing an alternate reaction mechanism that has a lower activation energy than would be found in the absence of the catalyst. In a patent, 158407-04-6, molecular formula is C11H20BrNO2, introducing its new discovery.

6-PHENYLPYRIMIDINONES AS PIM MODULATORS

A compound having Formula I or II (Formula I) or (Formula II), or a pharmaceutically acceptable salt thereof, wherein X, Z, R1, R2, R11 and R12 are as defined in the specification; pharmaceutical compositions thereof; and methods of use thereof.

158407-04-6, Each elementary reaction can be described in terms of its molecularity, the number of molecules that collide in that step. The slowest step in a reaction mechanism is the rate-determining step.you can also check out more blogs about 158407-04-6

Reference£º
Piperidine – Wikipedia,
Piperidine | C5H22575N – PubChem

 

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.158407-04-6,tert-Butyl 4-(bromomethyl)piperidine-1-carboxylate,as a common compound, the synthetic route is as follows.

Step B: tert-Butyl 4-{[(5-cyanopyridin-2-yl)sulfanyllmethyl|piperidine-l-carboxylate 6-Sulfanylpyridine-3-carbonitrile (220 mg, 1.6 mmol) was dissolved in DMF (10 mL) in a round bottom flask at room temperature, tert-butyl 4-(bromomethyl) piperidine-l-carboxylate (530 mg, 1.9 mmol) was added, followed by potassium carbonate (440 mg, 3.2 mmol). The resulting mixture was heated to 80 C and stirred over night. The reaction mixture was diluted with EtOAc, washed with water and brine, then dried over anhydrous sodium sulfate, filtered and concentrated. The resulting residue was purified by MPLC (eluent: 0->100% EtOAc/Hexane gradient) to provide tert-Butyl 4-{[(5-cyanopyridin-2-yl)sulfanyl]methyl}piperidine-l- carboxylate. NMR delta (ppm)(500 Hz, CDCh): 8.64 (d, J= 2.1 Hz, 1H), 7.64 (dd, J= 8.4, 2.2 Hz, 1H), 4.11 (m, 2 H), 3.17 (d, J= 6.8 Hz, 2H), 2.68 (m, 2 H), 1.84-1.80 (m, 2 H), 1.80-1.72 (m, 1 H), 1.55 (s, 9 H), 1.28-1.16 (m, 2 H). LC-MS (IE, m/z): 356 [M + 23]+.

158407-04-6, The synthetic route of 158407-04-6 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; MERCK SHARP & DOHME CORP.; WALSH, Shawn; PASTERNAK, Alexander; CATO, Brian; FINKE, Paul, E.; FRIE, Jessica; FU, Qinghong; KIM, Dooseop; PIO, Barbara; SHAHRIPOUR, Aurash; SHI, Zhi-Cai; TANG, Haifeng; WO2013/39802; (2013); A1;,
Piperidine – Wikipedia
Piperidine | C5H11N – PubChem

 

158407-04-6, tert-Butyl 4-(bromomethyl)piperidine-1-carboxylate is a piperidines compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

158407-04-6, To a solution of 3-iodo-1H-pyrazolo[3,4-d]pyrimidin-4-amine (3 g, 11.49 mmol, 1.0 equiv) in DMA (30 mL) was added tert-butyl 4-(bromomethyl)piperidine-1-carboxylate (3.36 g, 12.07 mmol, 1.05 equiv) and K2CO3 (4.77 g, 34.48 mmol, 3.0 equiv), then the reaction was stirred at 80 C for 3 h. The reaction mixture was filtered to remove K2CO3 and the filtrate was poured into H2O (200 mL). A solid precipitated was then filtered to give tert- butyl 4-((4-amino-3-iodo-1H-pyrazolo[3,4-d]pyrimidin-1-yl)methyl)piperidine-1-carboxylate (3 g, 57% yield) as light yellow solid. LCMS (ESI) m/z: [M + H] calcd for C16H23IN6O2: 459.10; found 459.1.

The synthetic route of 158407-04-6 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; REVOLUTION MEDICINES, INC.; SEMKO, Christopher Michael; WANG, Gang; BURNETT, G. Leslie; AGGEN, James Bradley; KISS, Gert; CREGG, James Joseph; GLIEDT, Micah James Evans; PITZEN, Jennifer; LEE, Julie Chu-Li; WON, Walter; THOTTUMKARA, Arun P.; GILL, Adrian Liam; (356 pag.)WO2019/212991; (2019); A1;,
Piperidine – Wikipedia
Piperidine | C5H11N – PubChem

 

158407-04-6, tert-Butyl 4-(bromomethyl)piperidine-1-carboxylate is a piperidines compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

Method H; Synthesis of 2-Methyl-2-(piperidin-4-ylmethanesulfonyl)-N-(5-trifluoromethyl-pyridin-2-yl)-propionamide (Example 98, Table 17) Step 1: Synthesis of 4-[1-Methyl-1-(5-trifluoromethyl-pyridin-2-ylcarbamoyl)-ethylsulfanylmethyl]-piperidine-1-carboxylic acid tert-butyl ester To a solution of 200 mg (0.654 mmol) of thioacetic acid S-[1-methyl-1-(5-trifluoromethyl-pyridin-2-ylcarbamoyl)-ethyl]ester (synthesized according to Method F, step 1) in ethanol (2 mL) were added 363 mg (1.31 mmol) of 4-bromomethyl-piperidine-1-carboxylic acid tert-butyl ester and 141 mg (2.61 mmol) of sodium methoxide at room temperature. The reaction was heated to 130 C. for 0.5 h within a microwave (CEM Discover). The reaction mixture was concentrated under reduced pressure. The residue was dissolved in DCM (4 mL) and washed with saturated aqueous NaHCO3 solution (5 mL). The organic phase was dried over Na2SO4, filtered and the filtrate was concentrated under reduced pressure to yield 375 mg of 4-[1-methyl-1-(5-trifluoromethyl-pyridin-2-ylcarbamoyl)-ethylsulfanylmethyl]-piperidine-1-carboxylic acid tert-butyl ester., 158407-04-6

As the paragraph descriping shows that 158407-04-6 is playing an increasingly important role.

Reference£º
Patent; Berry, Angela; Cirillo, Pier Francesco; Hickey, Eugene Richard; Riether, Doris; Thomson, David; Zindell, Renee M.; Blumire, Nigel; Chowdhury, Chandana; Ermann, Monika; Jenkins, James Edward; Mushi, Innocent; Palmer, Christopher Francis; Taylor, Malcolm; US2008/81822; (2008); A1;,
Piperidine – Wikipedia
Piperidine | C5H11N – PubChem

 

158407-04-6, tert-Butyl 4-(bromomethyl)piperidine-1-carboxylate is a piperidines compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

tert-butyl 4-((2S)-8-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl-6-oxo-2-trifluoromethyl-3,4-dihydro-2H,6H-pyrimido[1,2-a]pyrimidin-1-ylmethyl)piperidine-1-carboxylate 788 mg (2.84 mmol) of tert-butyl 4-bromomethylpiperidine-1-carboxylate and 425 mg (2.84 mmol) of sodium iodide are added to a solution of 690 mg (2.18 mmol) of (8S)-2-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one and 2.13 g (6.54 mmol) of cesium carbonate in 10 mL of acetonitrile. The reaction mixture is heated in a Biotage microwave reactor at 100 C. for 3 hours. The reaction medium is evaporated to dryness and the residue is taken up in EtOAc and washed with water and with saturated NaCl. The organic phase is dried over magnesium sulfate and evaporated to dryness. The residue is purified by chromatography on silica gel (eluent: 95/5 DCM/MeOH) to give 510 mg of tert-butyl 4-((2S)-8-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl-6-oxo-2-trifluoromethyl-3,4-dihydro-2H,6H-pyrimido[1,2-a]pyrimidin-1-ylmethyl)piperidine-1-carboxylate, the characteristics of which are as follows: LC/MS (method G): ESI+ [M+H]+: m/z 514 tr (min)=2.45 1H NMR (300 MHz, delta in ppm, DMSO-d6): 0.93-1.03 (m, 1H), 1.11-1.32 (m, 3H), 1.38 (s, 9H), 1.44-1.64 (m, 2H), 1.76-1.91 (m, 2H), 1.99-2.39 (m, 3H), 2.78-3.32 (m, 5H), 3.60 (m, 1H), 3.71 (m, 1H), 3.86-3.99 (m, 2H), 4.06-4.19 (m, 2H), 4.48-4.92 (m, 3H).

158407-04-6, The synthetic route of 158407-04-6 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; El-Ahmad, Youssef; Filoche-Romme, Bruno; Ganzhorm, Axel; Marciniak, Gilbert; Muzet, Nicolas; Ronan, Baptiste; Vivet, Bertrand; Zerr, Veronique; US2015/183804; (2015); A1;,
Piperidine – Wikipedia
Piperidine | C5H11N – PubChem